FDA approved a new drug, Corlanor (ivabradine), for chronic heart failure patients. Corlanor decreases heart rate to a normal range by blocking a function of the heart’s natural pacemaker cells. Corlanor is used together with current standard of therapy beta blockers for patients with stable heart failure symptoms and heart rate greater than 70 beats per minute. The clinical trial comparing Corlanor with a placebo showed significant reduction of rehospitalization, thus decrease cost associated with chronic heart failure. The common side effects were excessive slowing of the heart rate, high blood pressure, atrial fibrillation, and temporary vision disturbance. How would you weigh the risks and benefits of newly approved Corlanor?
For more information, please see Reuters.
Image courtesy of [smokedsalmon]/http://www.freedigitalphotos.net